Combined two-dose hepatitis A and B vaccine (AmBirix™1)

Drugs

Volumn 63, Issue 2, 2003, Pages 207-213

  Jarvis, Blair ^a   Figgitt, David P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ANTIBODY TITER; DRUG MECHANISM; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH CARE COST; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; PAIN; REVIEW; SEROCONVERSION; SEROPREVALENCE; TREATMENT INDICATION; VACCINATION; VIRUS HEPATITIS;

ADOLESCENT; CHILD; HEPATITIS A VACCINES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INJECTIONS, INTRAMUSCULAR; RANDOMIZED CONTROLLED TRIALS; VACCINES, COMBINED;

HEPATITIS A VIRUS; HEPATITIS B VIRUS;

EID: 0037251931     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363020-00006     Document Type: Review

References (18)

1. Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis prevention Board. BMJ 1997; 314: 1033-6
2. CDC. Update: recommendations to prevent hepatitis B virus transmission - United States. JAMA 1999: 281: 790
3. Core Working Party for Asia-Pacific Consensus on hepatitis A and C. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. J Gastroenterol Hepatol 2000; 15 (8): 825-41
4. Mahoney FJ. Update on diagnosis management and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12: 351
5. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336: 196-203
6. Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J Med Virol 2002; 67 (3): 433-9
7. Chang M-H, Shau W-Y, Chen C-J, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 2000; 284 (23): 3040-2
8. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996; 276 (11): 906-8
9. Chang M-H, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336 (26): 1855-9
10. Loscher T, Keystone JS, Steffen R. Vaccination of travelers against hepatitis A and B. J Travel Med 1999 Jun; 6 (2): 107-14
11. Koff RS. The case for routine childhood vaccination against hepatitis A. N Engl J Med 1999 Feb 25; 340 (8): 644-5
12. Tanaka J. Hepatitis A shifting epidemiology in Latin America. Vaccine 2000; 18 Suppl. 1: S57-60
13. Lee A, Cheng F, Lau L, et al. Should adolescents be vaccinated against hepatitis A: the Hong Kong experience. Vaccine 2000; 18: 941-6
14. GlaxoSmithKline Biologicals. AmBirix European Summary of Product Characteristics. 2002 Aug
15. Van Damme P, Leroux-Roels G, Law B, et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol 2001 Sep; 65 (1): 6-13
16. Van Der Wielen M, Van Damme P, Collard F. A two dose schedule for combined hepatitis A and hepatitis B vaccination in children ages one to eleven years. Pediatr Infect Dis J 2000 Sep; 19 (9): 848-53
17. Levie K, Beran J, Collard F, et al. Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and three dose schedule in adolescents aged 12-15 years. Vaccine 2002 Jun 7; 20 (19-20): 2579-84
18. Burgess MA, Rodger AJ, Waite SA, et al. Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomised study. Vaccine 2001 Sep 14; 19 (32): 4835-41